| Health / Medical Topics |
P53-Synthetic Long Peptides Vaccine
A peptide vaccine consisting of 10 synthetic long peptides (SLPs), 25-30 amino acids in size and derived from the middle portion of p53 (amino acids 70-251), mixed with the adjuvant Montanide ISA-51 with potential immunostimulatory and antitumor activities. Upon administration, p53 synthetic long peptide (70-251) vaccine may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against p53-expressing tumor cells. p53, a tumor associated antigen (TAA), may be overexpressed in variety of cancer cell types. (NCI Thesaurus)
YOU MAY ALSO LIKE
An orally available spiro-oxindole HDM2 (human double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, the p53-HDM2 protein-protein interaction inhibitor…
p53 activation is induced by a number of stress signals, including DNA damage, oxidative stress and activated oncogenes. The p53 protein is…
p53 is a transcription factor who's activity is regulated by phosphorylation. The function is p53 is to keep the cell from progressing…
A peptide-based cancer vaccine composed of amino acids 264 to 272 of the wild-type protein encoded by the P53 gene. p53 peptide…
A tumor suppressor gene that normally inhibits the growth of tumors. This gene is altered in many types of cancer.
p53 apoptosis effector related to PMP-22 (193 aa, ~21 kDa) is encoded by the human PERP gene. This protein is involved in…
